Shanghai Henlius Biotech's (HKG:2696) new drug application for HLX14 has been accepted by China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.
The indications for the drug include the treatment of osteoporosis in postmenopausal women and men at high risk of fractures, as well the treatment of glucocorticoid-induced osteoporosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.